A Gene Transfer Study Using Experimental SPK-8011 for Hemophilia A (poor blood clotting)
This research study will help us learn if the study product (SPK-8011) is safe and effective in reducing bleeding for treating hemophilia A.
Summary
- Eligibility
- for males ages 18 years and up (full criteria)
- Location
- at Sacramento, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Adam Giermasz, MD, PhD
Description
Summary
Official Title
Details
Keywords
Eligibility
Locations
Lead Scientist at UC Davis
- Adam Giermasz, MD, PhD
Associate Professor, Hematology and Oncology, School of Medicine. Authored (or co-authored) 48 research publications
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Spark Therapeutics
- Links
- Sign up for this study
- ID
- NCT03003533
- Phase
- Phase 1/2 Hemophilia Research Study
- Study Type
- Interventional
- Participants
- Expecting 50 study participants
- Last Updated